There are currently 87 active clinical trials seeking participants for Lymphoma research studies. The states with the highest number of trials for Lymphoma participants are Ohio, Illinois, California and New York.
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
NCT06218602
Recruiting
To find out if adding treatment with fecal microbiota transplantation (FMT) is effective at treating gut-related side effects of antibiotic treatment in participants who are receiving standard therapy with anti-CD19 chimeric antigen receptor T-cell (CAR-T cell) therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
Vaccine Responses in Patients With B Cell Malignancies
NCT05170399
Recruiting
Background: People with B cell malignancies (blood cancers) often cannot mount a full immune response to infections or certain vaccines. Bruton tyrosine kinase inhibitors (BTKis), which are used to treat blood cancers, may also negatively affect a person s response to certain vaccines. Researchers want to learn more about vaccine responses in people with certain types of blood cancers. The findings may help develop better vaccine strategies for people with these cancers. Objective: To learn h... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Lymphoma
Register for Updates
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
NCT06733441
Recruiting
The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Washington University School of Medicine, St. Louis, Missouri +3 locations
Conditions: Lymphoma
Register for Updates
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
NCT06001385
Recruiting
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it aims to answer are: * Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? * Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Mayo Clinic Arizona, Phoenix, Arizona +31 locations
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
Register for Updates
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
NCT04570423
Recruiting
The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.
Gender:
ALL
Ages:
Between 1 month and 17 years
Trial Updated:
05/22/2025
Locations: New York Medical College, Valhalla, New York +3 locations
Conditions: Solid Tumors, Lymphoma
Register for Updates
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
NCT02974647
Recruiting
The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib may cause T or NK-cell lymphomas to shrink.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: University of Miami, Miami, Florida +9 locations
Conditions: Lymphoma
Register for Updates
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
NCT05011045
Recruiting
This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Central Nervous System Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma, Secondary Central Nervous System Lymphoma
Register for Updates
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma
NCT04571138
Recruiting
Patients with relapsed or refractory leukemia or lymphoma are often refractory to further chemotherapy. In this study, the investigators will attempt to use T cells obtained directly from the patient, which can be genetically engineered to express a chimeric antigen receptor (CAR). The CAR used in this study can recognize CD22, a protein expressed on the surface of leukemia and lymphoma cells. The phase 1 part of this study will determine the safety and appropriate dose level of these CAR T cell... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
05/20/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +4 locations
Conditions: Leukemia, Lymphoma
Register for Updates
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
NCT01608152
Recruiting
This trial collects feedback from patients to develop a video game in improving the outcomes in stem cell transplant survivors. A video game may help to improve health behaviors for leukemia or lymphoma patients after stem cell transplant.
Gender:
ALL
Ages:
Between 15 years and 39 years
Trial Updated:
05/19/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Leukemia, Lymphoma
Register for Updates
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
NCT06475235
Recruiting
This research study is studying if the investigational drug, Pembrolizumab, in combination with chemotherapy helps primary central nervous system lymphoma with acceptable side effects. This research study involves a combination of the below drugs: * Pembrolizumab (a type of monoclonal antibody) * Methotrexate (a type of anti-metabolite) * Temozolomide (a type of alkylating agent) * Rituximab (a type of antibody)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Lymphoma, Primary Central Nervous System Lymphoma
Register for Updates
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
NCT06049134
Recruiting
To compare the effects of a pneumococcal vaccine called PCV20 when given as a single dose versus a boosted regimen to patients who previously received anti-CD20 therapy as treatment for B cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
NCT05676450
Recruiting
To test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: MD Anderson Cancer Center, Houston, Texas +1 locations
Conditions: Lymphoma
Register for Updates